La Jolla Diagnostics
This article was originally published in The Tan Sheet
Executive Summary
Acquires domestic and international marketing rights from an undisclosed source for a rapid home pregnancy test that has been available in the U.S. for the past two years, the company reports Jan. 6. Initial marketing efforts will focus on sub-Saharan Africa and other international markets, where the company currently markets HIV and tuberculosis diagnostic tests. La Jolla plans to sell the product in the U.S. at a "substantially lower price" than the current $8 average, but a launch is not expected for several months